Europe's largest drug maker says investment will help meet increasing demand for its adult and pediatric vaccines, including the new cancer shot Cervarix, which is expected to gain regulatory approval in 2007. GlaxoSmithKline has been investing heavily in vaccines business and has been buying companies and technologies.
Source: Earth Times.org